Company Profile
Artelo Biosciences Stock Price, News & Analysis
- Ticker:
- ARTL
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.75 USD (+0.15%)
Close
Last updated: August 6, 2026
5.05M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ARTL was little changed and closed at $0.7524. No new same-company headline was identified in the current news window.
Company overview
Lipid-Signaling Therapeutics
Artelo Biosciences develops medicines that modulate cannabinoid and fatty-acid signaling pathways. Its portfolio addresses cancer supportive care, pain and neuropsychiatric conditions through distinct small-molecule mechanisms.
ART27.13
ART27.13 is a peripherally selective cannabinoid-receptor agonist in Phase 2 development for cancer anorexia-cachexia syndrome. The goal is to improve appetite, weight, lean body mass and activity without central psychoactive effects.
ART26.12
ART26.12 is a fatty-acid-binding-protein 5 inhibitor being developed as a non-opioid, non-steroidal analgesic, initially for chemotherapy-induced peripheral neuropathy. A Phase 1 single-ascending-dose study showed favorable safety and predictable pharmacokinetics.
ART12.11
ART12.11 is a proprietary cocrystal of cannabidiol and tetramethylpyrazine designed to improve the pharmaceutical properties of CBD. Preclinical work supports potential development in anxiety or depression-related indications.
Future catalysts
Opening of Phase 1 multiple-ascending-dose enrollment for ART26.12 planned in the third quarter of 2026.
Toxicology results for ART12.11 expected in 2026.
First-in-human ART12.11 study planned for the first half of 2027, subject to toxicology results.
Recent news
- 01
- 02
- 03
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026
Source: Artelo Biosciences
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Artelo Biosciences (ARTL)?
Artelo Biosciences (ARTL) most recently closed at 0.75 USD, a +0.15% move versus the previous session.
What is the market cap of Artelo Biosciences (ARTL)?
Artelo Biosciences currently has a market capitalization of 5.05M USD on BioPharmSignal.
What does Artelo Biosciences do?
Lipid-Signaling Therapeutics Artelo Biosciences develops medicines that modulate cannabinoid and fatty-acid signaling pathways. Its portfolio addresses cancer supportive care, pain and neuropsychiatric conditions through distinct small-molecule mechanisms. ART27.13 ART27.13 is a peripherally selective cannabinoid-receptor agonist in Phase 2 development for...
On which exchange is ARTL stock listed?
Artelo Biosciences (ARTL) is associated with NASDAQ, United States, Biopharma.
What is Lipid-Signaling?
Lipid-Signaling Therapeutics Artelo Biosciences develops medicines that modulate cannabinoid and fatty-acid signaling pathways.
Which conditions is Artelo Biosciences targeting with Lipid-Signaling?
Artelo Biosciences is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Artelo Biosciences describe recent progress with Lipid-Signaling?
Opening of Phase 1 multiple-ascending-dose enrollment for ART26.12 planned in the third quarter of 2026. Toxicology results for ART12.11 expected in 2026. First-in-human ART12.11 study planned for the first half of 2027, subject to toxicology results.
What is Therapeutics?
Lipid-Signaling Therapeutics Artelo Biosciences develops medicines that modulate cannabinoid and fatty-acid signaling pathways.